Recurrent TRAK1::RAF1 Fusions in pediatric low-grade gliomas.
CRAF
RAF1
brain pathology
glioneuronal tumors
low-grade gliomas
Journal
Brain pathology (Zurich, Switzerland)
ISSN: 1750-3639
Titre abrégé: Brain Pathol
Pays: Switzerland
ID NLM: 9216781
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
30
03
2023
accepted:
16
06
2023
medline:
31
8
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Fusions involving CRAF (RAF1) are infrequent oncogenic drivers in pediatric low-grade gliomas, rarely identified in tumors bearing features of pilocytic astrocytoma, and involving a limited number of known fusion partners. We describe recurrent TRAK1::RAF1 fusions, previously unreported in brain tumors, in three pediatric patients with low-grade glial-glioneuronal tumors. We present the associated clinical, histopathologic and molecular features. Patients were all female, aged 8 years, 15 months, and 10 months at diagnosis. All tumors were located in the cerebral hemispheres and predominantly cortical, with leptomeningeal involvement in 2/3 patients. Similar to previously described activating RAF1 fusions, the breakpoints in RAF1 all occurred 5' of the kinase domain, while the breakpoints in the 3' partner preserved the N-terminal kinesin-interacting domain and coiled-coil motifs of TRAK1. Two of the three cases demonstrated methylation profiles (v12.5) compatible with desmoplastic infantile ganglioglioma (DIG)/desmoplastic infantile astrocytoma (DIA) and have remained clinically stable and without disease progression/recurrence after resection. The remaining tumor was non-classifiable; with focal recurrence 14 months after initial resection; the patient remains symptom free and without further recurrence/progression (5 months post re-resection and 19 months from initial diagnosis). Our report expands the landscape of oncogenic RAF1 fusions in pediatric gliomas, which will help to further refine tumor classification and guide management of patients with these alterations.
Identifiants
pubmed: 37399073
doi: 10.1111/bpa.13185
pmc: PMC10467040
doi:
Substances chimiques
Adaptor Proteins, Vesicular Transport
0
TRAK1 protein, human
0
Raf1 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13185Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
Références
Sci Adv. 2022 Feb 11;8(6):eabm2382
pubmed: 35138907
Mod Pathol. 2020 Aug;33(8):1466-1474
pubmed: 32123303
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Cell Biol. 2006 May 22;173(4):545-57
pubmed: 16717129
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
J Mol Diagn. 2020 Mar;22(3):368-375
pubmed: 31881335
Neuron. 2002 Dec 19;36(6):1063-77
pubmed: 12495622
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
Nat Med. 2014 Dec;20(12):1479-84
pubmed: 25384085
Acta Neuropathol. 2019 Apr;137(4):683-687
pubmed: 30848347
Brain Pathol. 2023 Sep;33(5):e13185
pubmed: 37399073
Brain Pathol. 1993 Jul;3(3):275-81
pubmed: 8293187
Cancer Res. 2008 Nov 1;68(21):8673-7
pubmed: 18974108
Brain Pathol. 2022 Jul;32(4):e13060
pubmed: 35218102
Nat Genet. 2013 Jun;45(6):602-12
pubmed: 23583981
Oncologist. 2021 Jan;26(1):e153-e163
pubmed: 32918774
Am J Dermatopathol. 2020 Dec;42(12):961-966
pubmed: 32769548
Cell. 2014 Jul 3;158(1):54-68
pubmed: 24995978
Protein Cell. 2018 Aug;9(8):693-716
pubmed: 28924745
J Mol Biol. 2008 Oct 10;382(3):638-51
pubmed: 18675823
Acta Neuropathol. 2018 Aug;136(2):239-253
pubmed: 29766299
J Neuropathol Exp Neurol. 2021 Dec 29;80(12):1099-1107
pubmed: 34850053
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5957-62
pubmed: 23533272
Oncologist. 2017 Dec;22(12):1478-1490
pubmed: 28912153
Childs Nerv Syst. 2016 Oct;32(10):1833-8
pubmed: 27659826
J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58
pubmed: 17086101
Cancer Genet. 2018 Apr;222-223:20-24
pubmed: 29666004
Nat Commun. 2014 Sep 10;5:4846
pubmed: 25204415
Acta Neuropathol. 2022 Apr;143(4):427-451
pubmed: 35169893
EMBO Mol Med. 2010 May;2(5):146-58
pubmed: 20432502
Cell Mol Life Sci. 2012 Jun;69(11):1799-811
pubmed: 22159586
Cancer Genet. 2016 Oct;209(10):440-444
pubmed: 27810072
Oncogene. 2009 May 21;28(20):2119-23
pubmed: 19363522
Oncogene. 2017 Nov 9;36(45):6348-6358
pubmed: 28806393
Acta Neuropathol Commun. 2020 Mar 12;8(1):30
pubmed: 32164789
Acta Neuropathol. 2016 Jun;131(6):833-45
pubmed: 26810070
Cancer. 1984 Dec 1;54(11):2505-12
pubmed: 6498740
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Oncogene. 2015 Sep 10;34(37):4845-54
pubmed: 25500544